Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Anuradha Arun

Internal Medicine Silver Spring, MD Medical Doctor

NPI 1003997479 CMS profile 1160752

9801 Georgia Ave, Suite 224, Silver Spring, MD 20902

Open in the dashboard

General payments

$3,680

180 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anuradha Arun of Silver Spring, MD is reported in the CMS Open Payments database as having received $3,680 across 180 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $417 18
2024 General $783 34
2023 General $630 31
2022 General $585 26
2020 General $658 35
2019 General $607 36

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anuradha Arun
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Anuradha Arun were reported at $417. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Anuradha Arun Internal Medicine median Middle half National median
2019 $607 $159 $48–$570 $163
2020 $658 $119 $33–$402 $114
2021 $0 $135 $37–$521 $132
2022 $585 $141 $42–$496 $149
2023 $630 $149 $45–$519 $160
2024 $783 $154 $47–$537 $164
2025 $417 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $717 38 payments
  2. Novo Nordisk Inc $547 23 payments
  3. Lilly USA, LLC $482 22 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $295 14 payments
  5. Amgen Inc. $290 15 payments
  6. Janssen Pharmaceuticals, Inc $162 8 payments
  7. AbbVie, Inc. $149 6 payments
  8. Pfizer Inc. $140 9 payments
  9. Horizon Therapeutics plc $119 5 payments
  10. Exact Sciences Corporation $88 4 payments
  11. Other $692 36 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,662 178 payments
  2. Education $19 2 payments
Products named General payments · program years 2019–2025
  1. RYBELSUS $421 16 payments
  2. FARXIGA $348 18 payments
  3. Ozempic $319 17 payments
  4. JARDIANCE Diabetes $270 13 payments
  5. MOUNJARO $260 12 payments
  6. EVENITY $208 11 payments
  7. XIGDUO $180 11 payments
  8. JARDIANCE Diabetes $177 8 payments
  9. Prolia $174 9 payments
  10. XARELTO $162 8 payments
  11. Other $2,470 126 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 55 drugs

Part D claims

2,837

Median for Internal Medicine: 777

Drug cost

$211,705

Median for Internal Medicine: $73,373

Branded share of claims

13.6%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 54 $72,529
Ozempic Semaglutide Brand 16 $29,870
Januvia Sitagliptin Phosphate Brand 25 $23,900
Farxiga Dapagliflozin Propanediol Brand 18 $21,186
Janumet Sitagliptin Phos/Metformin Hcl Brand 15 $18,538
Tradjenta Linagliptin Brand 21 $14,779
Atorvastatin Calcium Generic 319 $2,643
Rosuvastatin Calcium Generic 159 $2,447
Amlodipine Besylate Generic 313 $2,069
Losartan Potassium Generic 203 $1,798

The 10 drugs with the highest cost, of 55 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 46 billing codes

Paid by Medicare

$254,541

Of which drugs: $22,672

Medicare patients

547

Average age 73

Services billed

4,428

376 women, 171 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Diabetes 37%
Chronic kidney disease 25%
Osteoporosis 24%
Depression 20%
Ischemic heart disease 16%
Cancer 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 131 134 $10,681
Pcv20 vaccine im 90677 Office 35 35 $9,857
Vaccine for influenza for administration into muscle, 0.5 ml dosage 90656 Office 16 16 $350

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $116
$116 — —
MOUNJARO
  • Lilly USA, LLC $95
$95 — —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $69
$69 — —
JARDIANCE
  • Lilly USA, LLC $32
  • Boehringer Ingelheim Pharmaceuticals, Inc. $25
$58 54 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $46
$46 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

180 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record